SCHEMBL1853808

SCHEMBL1853808

CC(C)(C)OC(=O)N1C[C@@H](F)C[C@H]1C(=O)Nc1c(C(N)=O)oc2ccc(Cl)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.51
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
ALDH1A1 P00352 4/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
ABL1 P00519 2/20 0.39
BCR P11274 2/20 0.39
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
CFD P00746 4/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1853806 1.00 KDM4E (0.51) KDM4EMAPK1MEN1KMT2APOLB
SCHEMBL1855587 1.00 KDM4E (0.51) KDM4EMAPK1MEN1KMT2APOLB
SCHEMBL1856066 0.91 KDM4E (0.52) KDM4EMAPK1MEN1KMT2APOLB
SCHEMBL1856064 0.91 KDM4E (0.52) KDM4EMAPK1MEN1KMT2APOLB
SCHEMBL1855450 0.90 KMT2A (0.43) KDM4EMEN1KMT2APOLBCYP1A2
SCHEMBL1856586 0.90 KMT2A (0.43) KDM4EMEN1KMT2APOLBCYP1A2
SCHEMBL1855448 0.90 KMT2A (0.43) KDM4EMEN1KMT2APOLBCYP1A2
SCHEMBL1851107 0.89 CFD (0.43) KDM4EMEN1KMT2APOLBCYP1A2
SCHEMBL1851790 0.89 CFD (0.43) KDM4EMEN1KMT2APOLBCYP1A2
SCHEMBL1851792 0.89 CFD (0.43) KDM4EMEN1KMT2APOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed
EP-2097419-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS Exelixis, Inc. (US) 2009-09-09 EP disclosed
WO-2009086264-A1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS, INC. (US) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 KDM4E 1855/4885MAPK1 3703/4885MEN1 1111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.